|
Dec 17, 2003:
the FDA qualified the Mediscience Technology Corp. for both reduced or waived
FDA fees for its 2004 medical device 510K market approval submissions
Dec 3, 2003:
Mediscience Technology Corp. OTC-MDSC Secures Exclusive World-Wide License to US
Molecular Imaging Patent Applications, Expected to Extend Core Technology
Additional 17+ Years
Nov. 24, 2003:
Breakthrough in Detecting Cancerous Tissue via Stokes Shift
Emission Spectroscopy
July 16, 2003:
CCNY Receives $6 Million NASA Grant To Enhance Photonics
Research
June 4, 2003:
Mediscience Technology Announces Formation Of New
Subsidiary To Develop
Potential Clinical Application For Non-Invasively
Diagnosis Of Prostate Cancers
April 28, 2003:
Mediscience Technology Appoints Michael Engelhart President and
Chief Operating Officer Effective Immediately
March 14, 2003:
Mediscience Technology Appoints Michael Engelhart To
The Board Of Directors
January 22, 2003:
Mediscience Technology Selects THM Group For Commercialization Phase Of
Cancer Detection Technology
June 30, 2002:
The Research Foundation City University Of New York (Rfcuny) Acquires Major
Equity Position In Mediscience Technology Corp.
July 12, 2001:
Mediscience Technology Selects Mr. Sidney Braginsky as new President and COO
March. 8, 1999:
FDA Approves Phase II in Vivo use of Medisience CD-Scan Optical System as
Non-Significant
Risk Device in Yale University/Mediscience significant Womens Health Study
March. 24, 1999:
Mediscience Cd-Scan Effective in Cornell/New York Medical Barrett's Esophageal Relux
Study in Distinguishing Normal Esophageal Tissue From Barrett's or Adenocarcinoma
June 3, 1997:
MEDISCIENCE US PATENT ISSUED: Techniques to detect cellular malignancy for PAP
SMEAR type samples
March 19, 1997:
Mediscience Announces "Incubator" Space on Campus
Jan. 8, 1997:
Mediscience Announces FDA "IDE" Approval
THE FDA QUALIFIED THE MEDISCIENCE TECHNOLOGY CORP. FOR BOTH
REDUCED OR WAIVED
FDA FEES FOR ITS 2004 MEDICAL DEVICE 510K MARKET APPROVAL SUBMISSIONS
CHERRY HILL, N.J., (Dec 17, 2003) -
Mediscience Technology Corp. (MTC), (OTCBB:MDSC) of Cherry Hill, New Jersey,
a developer of imaging
technology for molecular detection of cancer and physiological change,
announced: on December 11, 2003 the FDA, after review, qualified the Company
under MDUFMA (The Medical Device User Fee and Modernization Act of 2002)
allowing both reduced or waived FDA fees for its 2004 medical device 510K
market
approval submissions." and Company participation in expedited FDA review
through
FDA clinical inspections conducted independently by third party FDA approved
"accredited" persons, directly employed by Mediscience.
President and Chief Operating Officer Michael Engelhart stated, "we are
making
steady progress in all aspects of our business and continue to expand our
leadership in the Optical Biopsy field."
INVESTOR NOTICE:
Certain of the matters discussed in this announcement contain
forward-looking
statements that involve material risks to and uncertainties in the company's
business that may cause actual results to differ materially from those
anticipated by the statements made herein. Such risks and uncertainties
include
among other things, the availability of financing, the company's ability to
implement its long-range business plan for various applications of its
technology; the company's ability to enter into agreements with any necessary
marketing and/or distribution partners; the impact of competition, the
obtaining
and maintenance of any necessary US regulatory clearances applicable to
applications of the company' technology; and management of growth and other
risked and uncertainties that may be detailed from time to time in the
company's
reports filed with the Securities and Exchange Commission. This disclosure is
intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and
Section 7
and 7.0 as well as all applicable and presently effective Sarbanes-Oxley
disclosure requirements under Regulation G.
Top of page
MEDISCIENCE TECHNOLOGY CORP. OTC-MDSC SECURES EXCLUSIVE WORLD-WIDE LICENSE TO US
MOLECULAR IMAGING PATENT APPLICATIONS, EXPECTED TO EXTEND CORE TECHNOLOGY
ADDITIONAL 17+ YEARS
CHERRY HILL, N.J., (Dec 3, 2003) -
Mediscience Technology Corp. (MTC), (OTCBB:MDSC) of Cherry Hill, New Jersey, a
developer of imaging technology for molecular detection of cancer and physiological
change, announced its contractual acquisition of two exclusive world-wide
licenses for US patent applications filed by The Research Foundation City
University of New York (RFCUNY). 1. 'Stokes-Shift Fluorescence spectroscopy
for detection of disease and physiological state of specimen'and 2. 'Three-dimensional
Radiative Transfer Tomography for Turbid Media.'The work results from the Company's
continual 10-year+ University research funding relationship. President and Chief
Operating Officer Michael Engelhart and CUNY inventor Dr. Robert Alfano state that
'the patents, when issued, would extend the Company's core technology in Optical
Biopsy for an additional 17+ years, thus expanding, maintaining and continuing
our IP leadership in the Optical Biopsy field.'
NOTE: SEE: Mediscience SEC 8-k filing dated: December 3, 2003
Web Page:
medisciencetech.com See (IEEE Journal of selected topics in Quantum
Electronics March-April 2003 Vol. 9 Dr. Alfano page 148 and page 189.)
INVESTOR NOTICE:
Certain of the matters discussed in this announcement contain forward-looking
statements that involve material risks to and uncertainties in the company's
business that may cause actual results to differ materially from those anticipated
by the statements made herein. Such risks and uncertainties include among other
things, the availability of financing, the company's ability to implement its
long-range business plan for various applications of its technology; the company's
ability to enter into agreements with any necessary marketing and/or distribution
partners; the impact of competition, the obtaining and maintenance of any necessary
US regulatory clearances applicable to applications of the company'technology; and
management of growth and other risked and uncertainties that may be detailed from
time to time in the company's reports filed with the Securities and Exchange Commission.
This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD,
disclosure and Section 7 and 7.0 as well as all applicable and presently effective
Sarbanes-Oxley disclosure requirements under Regulation G.
SOURCE: Mediscience Technology Corp.
Mediscience Technology Corp., Cherry Hill Michael Engelhart, [email protected]
or Peter Katevatis Esq. [email protected]
Top of page
BREAKTHROUGH IN DETECTING CANCEROUS TISSUE VIA STOKES SHIFT EMISSION SPECTROSCOPY
(Nov. 24, 2003) A research team at City College's Institute for
Ultrafast Spectroscopy and Lasers (IUSL) headed by Dr. Robert R. Alfano has announced
development of a new technique that is much more sensitive than conventional
fluorescence Spectroscopy to detect cancerous bio-molecules and structures.
Called "Stokes Shift Emission Spectroscopy," the method grows out of
seminal work done at the IUSL for the past two decades. In 1984. IUSL researchers first
demonstrated that light could be used to detect cancer from key molecules without
removing tissue.
According to Dr. Alfano, "this revolutionary breakthrough will make
optical biopsy the new medical frontier for cancer diagnosis and other medical
applications."
The emission and absorption of organic molecules in different hosts has
been investigated for over fifty years. Information on molecules in different states of
matter has been obtained by measuring emission and absorption spectra. For over four
decades spectroscopy has played an important role in understanding the fundamental
processes that occur in biology, chemistry and solid-slate physics.
Since the discoveries at the IUSL in 1984, spectroscopy has been
investigated as a tool to separate cancer, benign and surrounding tissue regions.
Typically, tissue is excited at a given wavelength to emit radiation at different
wavelengths, which are then used to characterize the tissue. The emission wavelengths
serve as "spectral fingerprints" for changes in the structure and content of various
proteins in the tissue. "For organic molecules, typically, the peaks of absorption
and emission occur at different wavelengths," Dr. Alfano said, "and the emission
band occurs at lower energy than the excitation band."
This difference between the emission and absorption peaks, known as the
Stokes Shift, depends in part on the polarity of the host environment surrounding the
emitting organic molecule. The new detection method developed at the IUSL combines the
fluorescence and absorption spectra of molecules in tissue and is known as "Stokes
Shift Emission Spectroscopy."
"The excitation and emission wavelengths are scanned simultaneously
with a fixed value between the excitation and emission wavelengths," according to Dr.
Alfano. "This approach is much more sensitive than ordinary fluorescence spectroscopy
and has delivered dramatically improved results in detecting changes in native
bio-molecules. It offers great promise, therefore, in detecting cancerous,
pre-cancerous and normal tissues."
When comparing the effectiveness of the Stokes Shift Emission
Spectroscopy (SS) method with conventional fluorescence spectroscopy it is clear that
this method is a more selective and a more effective means of distinguishing cancerous
from normal tissue.
Dr. Alfano called this as a "giant step forward for scientists at the
IUSL," who pioneered using optical spectroscopy to diagnose cancer without removing
tissue. The latest advance has the potential to detect tumors involving the breast,
cervix, gastrointestinal tract, head and neck, prostate, liver, brain, kidney, bladder
and other organs.
This work has been supported, in part, by
Mediscience Technology Corp. and funds from
organized research at The City University of New York.
Top of page
CCNY RECEIVES $6 MILLION NASA GRANT TO ENHANCE PHOTONICS RESEARCH
With support from a five-year $6 million University Research Center Program grant from
the National Aeronautics and Space Administration (NASA), City College has established a
Center for Optical Sensing and Imaging (COSI) designed to provide benefits in the
technical, scientific and social fields.
The Center’s primary goal is to develop improved sensing and imaging instruments and
techniques that will contribute to NASA research and future NASA missions. It will also
attract and train underrepresented minority students in related science and engineering
disciplines.
COSI is headed by the renowned Dr. Robert R. Alfano, Distinguished Professor of Science
and Engineering at CCNY, and Dr. Sam Ahmed, Herbert G. Kayser Professor of Electrical
Engineering.
“The high quality research, economic and social impacts that this program will
produce will be of significant value to the people of New York State and could aid in
the recovery of New York City,” said Dr. Alfano, who is also heads CCNY’s Institute
for Ultrafast Spectroscopy and Lasers, and directs New York State’s CUNY Center for
Advanced Technology in Ultrafast Photonics and Applications.
Dr. Alfano said COSI promises many tangible benefits, including increased educational
opportunities for minority students; a better-trained technical workforce; discoveries
that improve lives; and commercial innovations to help local businesses improve
efficiency and stay competitive.
The new Center will enable CCNY to expand its efforts in training and graduating
minority US students in the sciences and engineering by establishing a strong research,
education and outreach program to recruit, retain, mentor and train students.
CCNY is an important Other Minority University (OMU) and Hispanic Serving Institution
(HSI) with a strong record of training and educating talented students from
underrepresented ethnic groups for careers in the sciences and engineering.
“The program will train a minimum of 16 graduate and 10 under-graduate students
annually, and will also institute a vigorous K-12 science education program,” said Dr.
Manuel Zevallos, COSI’s Administrative and Technical Coordinator.
The scientific and technological objectives of COSI include development of optical
techniques and instruments (for both in-situ and ground- and satellite-based remote
applications) for:
- Development of lasers and detectors for use in remote sensing and optical
communications;
- Imaging targets and transmitting optical signal through clouds, fog, ice, and
rain;
- Detection of vegetation and land cover and measurement of the temperature of
ocean waters;
- Atmospheric and ocean monitoring;
- Sensing microorganisms (e.g., bacteria) in the environment.
The Center brings together the teams of two major existing NASA institutional programs
at City College: NASA IRA (Tunable Solid State Lasers) of the Institute for Ultrafast
Spectroscopy and Lasers (IUSL), and NASA PAIR (Remote Sensing and Environmental/Climat
Studies) of the International Center for Environmental Resources and Development (ICERD),
to form a complementary multi-disciplinary University Research Center.
CCNY also is home to the New York State Center for Advanced Technology in Ultrafast
Photonics and the NOAA Cooperative Center for Remote Sensing Science and Technology.
Other CCNY researchers participating in the Center include Dr. Swapan Gayen, Dr.
Vladimir Petricevic, Dr. Alvin Katz, Dr. Wubao Wang, Dr. Mikhail Sharonov and Dr.
Shengkun Zhang (Physics); Dr. Barry Gross, Dr. Fred Moshary and Dr. Ping-Pei Ho
(Electrical Engineering); Dr. Jeffrey Steiner (Earth and Atmospheric Sciences), and Dr.
Reza Khanbilvardi (Civil Engineering). Dr. Charles B. Watkins, Herbert G. Kayser
Professor of Mechanical Engineering, is COSI’s Educational and Outreach
Coordinator.
The CCNY researchers will maintain their close collaboration with NASA scientists and
engineers, as well as with partners from industry such as Lockheed Martin, Raytheon, and
GER Inc. to keep the research focused on NASA and real-world needs, and to facilitate
transfer of dual use technology to the marketplace.
Dr. Alfano said that COSI would enjoy strong support from CCNY and the City University
of New York (CUNY) and was a welcome new component to strengthen CUNY’s Photonics
Initiative.
Top of page
MEDISCIENCE TECHNOLOGY ANNOUNCES FORMATION OF NEW SUBSIDIARY TO DEVELOP
POTENTIAL CLINICAL APPLICATION FOR NON-INVASIVELY DIAGNOSIS OF PROSTATE CANCERS.
Cherry Hill, NJ (June 4, 2003) - Mediscience Technology (OTCBB - "MDSC"), a
medical diagnostics device company, is pleased to announce the formation of
"PROSCREEN, LLC". The Company, a wholly owned subsidiary of Mediscience
Technology has a potential clinical application for non-invasively diagnosing prostate
cancers without removing prostate tissues.
Prostate cancer has a high incidence and mortality rate for men. Every year,
nearly 180,000 new prostate cancer cases are diagnosed, and about 37,000
deaths annually are caused by prostate cancers in U.S. Current techniques for
detection of prostate cancers have limited accuracy. The regular methods for
monitoring prostate cancers are the prostate specific antigen (PSA) blood test and a
digital rectal examination (DRE). When the PSA level is elevated or the DRE
abnormal, there is a one-in-three chance that cancer is present. This can only
be confirmed by a needle biopsy of the prostate. In the biopsy, a number of
cores of prostate tissue are taken with a thin needle guided into selected
regions of the prostate with an ultrasound probe. Since the ultrasound imaging has
poor spatial resolution and contrast, and needle biopsy is invasive, better
methods are needed to develop high resolution and noninvasive techniques to
detect early small prostate cancers.
Michael Engelhart, President and COO of Mediscience Technology said, "The
prospects for this project are very exciting and can potentially enhance prostate
diagnosis and thereby create more favorable patient outcomes. We are
evaluating various methods to determine the best imaging technique. After we select
the best approach, we will develop a prototype spectral polarization imaging
unit with an optical fiber probe for prostate cancer detection, and engage in
performing clinical tests."
Engelhart added, "Our initial project will include three phases. In phase 1,
we will complete the evaluation of the imaging technique to select the best
imaging method for the device design. In phase 2, we will design the device,
purchase the parts, and build a prototype spectral polarization imaging unit with
an optical fiber probe. In phase 3, we will assist in performing clinical
test with a medical collaborator such as Hackensack University Medical Center and
modify the unit based on the clinical results."
Peter Katevatis, Chairman/CEO "The formation of "PROSCREEN, LLC" is
consistent with Mediscience's overall strategy of rolling out the company's
constellation model; the first of which was Photonics for Women's Oncology, LLC." We
continue to build our IP and exiting product base directly from our on-going
research relationship at CUNY's
INSTITUTE FOR LASERS AND ULTRA-FAST SPECTROSCOPY with the dedication of its
Director, Dr. Robert Alfano, and other associated medical and engineering staff.
About Mediscience Technology---Mediscience Technology Corp. is engaged in the
design and development of diagnostic medical devices that detect cancer using
light induced native tissue fluorescence spectroscopy to distinguish between
malignant normal, dysplastic or benign tissue.
This press release contains forward-looking statements involving risks and
uncertainties that may cause actual results to differ materially from those
indicated due to a number of factors. The Company's plans and objectives are based
on assumptions involving judgments with respect to future economic,
competitive, and regulatory and market conditions and future business decisions, all of
which are difficult or impossible to predict accurately and many of which are
beyond the control of the Company. Therefore, there can be no assurance that
the forward-looking statement will prove to be accurate. The Company's
documents filed with the SEC identify important factors that may cause the actual
results to differ materially from those indicated by the forward-looking
statements. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD,
disclosure and Section 7 and 7.0 as well as all applicable and presently
effective Sarbanes-Oxley disclosure requirements under Regulation G.
Reference:
Top of page
MEDISCIENCE TECHNOLOGY APPOINTS MICHAEL ENGELHART PRESIDENT
AND CHIEF OPERATING
OFFICER EFFECTIVE IMMEDIATELY.
Cherry Hill, NJ (April 28, 2003) - Mediscience Technology (OTCBB - "MDSC"), a medical diagnostics device company,
is pleased to announce that effective April 26, 2003, Michael Engelhart has been appointed President and Chief
Operating Officer Mr. Engelhart, 40, focus will be to evaluate and create
alternative strategies in an effort too maximize shareholder value and create
the needed funding mechanism. Effective April 26, 2003 Mr. Sidney Braginsky,
former President COO and the Registrant agreed to the termination of his
July 9, 2001 agreement effective retroactively as of July 9, 2001.
He will continue as a Board member providing consulting services to the
Board and President COO Michael Engelhart as needed.
"We are pleased to welcome someone with Michael's operational experience.
Mediscience continued progress will require a continued focus on operational
excellence as well as successful corporate development activities. Michael brings
a fresh perspective and a wealth of experience in ensuring that we make the best
use of our capital," said Peter Katevatis, Esq., Chairman and CEO.
"I appreciate the opportunity presented and confidence of the Mediscience
Board of Directors and Peter Katevatis, Chairman and CEO in what could be a
very important set of commercial ventures aimed at early cancer detection.
We are pleased with the pace of our continued development of the cervical
cancer detection device, where we have completed a final prototype.
We are encouraged by the early results of our capital raising and business
development activities that support and expedite the path to commercialization."
Said Michael Engelhart, President and COO of Mediscience.
About Mediscience Technology---Mediscience Technology Corp. is engaged in the
design and development of diagnostic medical devices that detect cancer using
light induced native tissue fluorescence spectroscopy to distinguish between
malignant normal, dysplastic or benign tissue.
This press release contains forward-looking statements involving risks and uncertainties
that may cause actual results to differ materially from those indicated due to a
number of factors. The Company's plans and objectives are based on assumptions
involving judgments with respect to future economic, competitive, and regulatory
and market conditions and future business decisions, all of which are difficult or
impossible to predict accurately and many of which are beyond the control of the Company.
Therefore, there can be no assurance that the forward-looking statement will prove
to be accurate. The Company's documents filed with the SEC identify important factors
that may cause the actual results to differ materially from those indicated by the
forward-looking statements. This disclosure is intended to satisfy: SEC Section 6,
6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable
and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.
Reference 8-K EDGAR filing April 28,2003/ Company's website at
medisciencetech.com/forms/8-K_4_29_03.htm
Contact Persons: Pres. COO Michael Engelhart (201) 818 0050
[email protected]
: Mediscience Technology Corp. Peter Katevatis Esq.
Chairman/CEO (856) 428 7952 [email protected].
Top of page
MEDISCIENCE TECHNOLOGY APPOINTS MICHAEL ENGELHART TO THE BOARD
OF DIRECTORS
Cherry Hill, NJ (March 14, 2003) - Mediscience Technology (OTCBB - "MDSC"), a medical diagnostics device company, is pleased to announce that effective March 13, 2003 Michael Engelhart has been appointed to the Board of Directors.
Mr. Engelhart, 40, is the CEO of THM Group, LLC, a New Jersey based strategic consulting organization. THM Group was retained by Mediscience to evaluate and create alternative strategies in an effort too maximize shareholder value.
"We are pleased to add to our board someone with Michael's operational experience in running strategic and corporate development functions at both large and small diversified companies. Mediscience continued progress will require a continued focus on operational excellence as well as successful corporate development activities. Michael will bring a fresh perspective and a wealth of experience in ensuring that we make the best use of our capital," said Peter Katevatis, Esq., Chairman and CEO of Mediscience.
About Mediscience Technology
Mediscience Technology Corp. is engaged in the design and development of diagnostic medical devices that detect cancer using light induced native tissue fluorescence spectroscopy to distinguish between malignant and normal or benign tissue
This press release contains forward-looking statements involving risks and uncertainties that may cause actual results to differ materially from those indicated due to a number of factors. The Company's plans and objectives are based on assumptions involving judgments with respect to future economic, competitive, and regulatory and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Therefore, there can be no assurance that the forward-looking statement will prove to be accurate. The Company's documents filed with the SEC identify important factors that may cause the actual results to differ materially from those indicated by the forward-looking statements.
Contact Persons: THMGROUP LLC Michael Engelhart (201) 818 0050 [email protected]: Mediscience Technology Corp. Peter Katevatis Esq. Chairman/CEO (856) 428 7952 [email protected]
For more information, visit the Company's website at medisciencetech.com.
Top of page
MEDISCIENCE TECHNOLOGY SELECTS THM GROUP FOR COMMERCIALIZATION PHASE OF CANCER
DETECTION TECHNOLOGY
For Immediate Release
Cherry Hill, NJ (January 22, 2003) - Mediscience Technology (OTCBB - "MDSC") of Cherry Hill, New Jersey, a company developing technology for molecular detection of cancer and physiological change, announced the appointment of THM Group, LLC as exclusive advisor to explore options for the company to commercialize its technology.
Peter Katevatis Esq., Chairman said" Mediscience has steadfastly developed its science to the conclusion of the research phase and now with the expert participation and assistance of THM Group expects to timely commercialize its paradigm platform technology.
Michael Engelhart, Chief Executive Officer of THM Group said, "We are looking forward to putting all of THM's capabilities behind the patent platform and prototype equipment of these exciting devices that we believe will significantly improve upon early cancer detection. We are pleased that Mediscience has entrusted us to provide options in an effort to maximize the return on their investment."
About Mediscience Technology
Mediscience Technology Corp. is engaged in the design and development of diagnostic medical devices that detect cancer- using light induced native tissue fluorescence spectroscopy to distinguish between malignant and normal or benign tissue.
medisciencetech.com
About THM Group
THM Group is focused on raising capital, carrying out project feasibility and business development projects for going businesses of private and public companies, and acting as an officer in early stage or troubled companies
This press release contains forward-looking statements involving risks and uncertainties that may cause actual results to differ materially from those indicated due to a number of factors. The Company's plans and objectives are based on assumptions involving judgments with respect to future economic, competitive, and regulatory and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Therefore, there can be no assurance that the forward-looking statement will prove to be accurate. The Company's documents filed with the SEC identify important factors that may cause the actual results to differ materially from those indicated by the forward-looking statements.
Contact Persons: THMGROUP LLC Michael Engelhart (201) 818 0050 [email protected]: Mediscience Technology Corp. Peter Katevatis Esq. Chairman/CEO (856) 428 7952 [email protected]
SEC 8-k filed 1/22,2003, and posted on Company web medisciencetech.com per Sarbanes-Oxley Full Disclosure requirements
Top of page
THE RESEARCH FOUNDATION CITY UNIVERSITY OF NEW YORK
(RFCUNY) ACQUIRES MAJOR EQUITY POSITION IN MEDISCIENCE
TECHNOLOGY CORP.
Cherry Hill, NJ (June 30, 2002) - Mediscience Technology Corp. (MTC), (OTCBB-
"MDSC") of Cherry Hill New Jersey, a developer of imaging technology for molecular
detection of cancer and physiological change, announced its revised contract with The
Research Foundation City University of New York (RFCUNY) effective May 31, 2002
The agreement, erases all (MTC) debt, reduces all company royalty rate obligations from
5% to 3.25% and affirms ownership and/or exclusive license of all Medical Applications
embodied in (MTC's) patent list, in exchange for consideration to (RFCUNY) of:
- Cash payment of $85,045.
- Issuance to (RFCUNY) of 283,228 SEC 144 shares.
- Issuance of a five (5) year Share Warrant to (RFCUNY) providing the right to
purchase six hundred thousand (600,000) SEC 144 shares at one dollar ($1.00) per
share.
(RFCUNY) now has a total 4% beneficial interest in Mediscience common Rule 144
shares, exercisable as Share Warrants at one dollar ($1.00) per share for a total of One
Million one hundred thousand (1,100,000) shares.
Effective May 31, 2002 (MTC) fully funded its new agreement-- Term: July 1, 2002 to
June 30, 2003, with "The Institute for Ultra fast Spectroscopy and Lasers Center for
Ultrafast Photonics and Mediphotonics Laboratory of City University of New York".
This 10-year+ relationship provides continual technical and research assistance to in
support of existing and anticipated clinical trials in the United States and India.
NOTE: SEE: Mediscience SEC/EDGAR 8-k filing 6/1/2002
Web Page: medisciencetech.com
INVESTOR NOTICE:
Certain of the matters discussed in this announcement contain forward-looking
statements that involve material risks to and uncertainties in the company's business that
may cause actual results to differ materially from those anticipated by the statements
made herein. Such risks and uncertainties include among other things, the availability of
financing, the company's ability to implement its long-range business plan for various
applications of its technology; the company's ability to enter into agreements with any
necessary marketing and/or distribution partners; the impact of competition, the obtaining
and maintenance of any necessary regulatory clearances applicable to applications of the
company' technology; and management of growth and other risked and uncertainties that
may be detailed from time to time in the company's reports filed with the Securities and
Exchange Commission.
Top of page
MEDISCIENCE TECHNOLOGY SELECTS MR. SIDNEY BRAGINSKY AS
NEW PRESIDENT AND COO
Cherry Hill, NJ -- July 12, 2001 (SEC-EDGAR filing 10-QSB)-- Effective July
9th 2001 Peter Katevatis, Esq. Chairman CEO on behalf of the Company entered
into an employment relationship with Mr. Sidney Braginsky as the new
President and COO. Mr. Braginsky was formerly with OLYMPUS OPTICAL LTD for 27
years most recently as President CEO of OLYMPUS AMERICA, Inc., the Olympus US
subsidiary. OLYMPUS LTD. is a multinational corporation headquartered in
Tokyo Japan and a world leader in microscopes, endoscopes, automatic blood
and fluid chemistry analyzers measuring research, industrial and consumer
products.
The Company will seek investment and/or corporate partners to support the
funding of
a joint effort between itself, Sarnoff Corporation, and the Mediphotonics
Laboratory of the City University of New York to develop and commercialize an
advanced, second generation version of its proprietary two-dimensional
fluorescence imaging system for early cancer detection.
Mr. Braginsky is a present board member of, NOVEN Pharmaceuticals, REDOX
Pharmaceuticals, ELECTRO-OPTICAL SYSTEMS, Inc., ESTEK CARDIOLOGY, Chairman of
Double D Venture Funds LLC and Chairman of the Board of City College of New
York's Robert Chambers Laboratory.
Top of page
MEDISCIENCE CD-SCAN EFFECTIVE IN CORNELL/NEW YORK MEDICAL BARRETT'S ESOPHAGEAL RELUX
STUDY IN DISTINGUISHING NORMAL ESOPHAGEAL TISSUE FROM BARRETT'S OR ADENOCARCINOMA
Cherry Hill, N.J., March 24, 1999 Mediscience Technology Corp. (OTC Bulletin Board: MDSC), pioneer developer and designer of non- invasive photonic technology used in medical diagnostic instruments that detect cancer/molecular changes based upon differentiations in the amount of light re-emitted from malignant and benign tissue reports findings published January 23-29, 1999 at the SPIE Optical Tomography and Spectroscopy of Tissue lll Conference by Principle Investigator Paul M. Basuk MD, New York Hospital-Cornell Medical Center together with researchers Dr. Alvin Katz and Dr. Howard Savage from the New York State Center of AdvancedTechnology in Ultra Fast Photonics, (CUNY) in a Mediscience supported "Investigation of Barrett's esophagus by ultraviolet and visible fluorescence emission and excitation spectroscopy." (Optical Biopsy, Section-presentation talk No. 3597-61).
Paul M. Basuk MD used the Mediscience CD-scan device on excised human gastrointestinal tissue to monitor patients with Barrett's esophagus, (a pre-malignant condition characterized by symptomatic gastroesophageal reflux), and concluded that "his work shows UV emission measurements can effectively distinguish normal esophageal tissue from Barrett's or adenocarcinoma. Further preliminary data also indicates that the combination of UV emission and excitation measurements can potentially separate non-dysplasia Barrett's from dysplasia and cancer as well as from normal tissues." On March 19, 1999 The New England Journal of Medicine Vol.340, No.11 reported on a study of "Symptomatic Gastrosophageal Reflux as a risk factor for esophageal Adinocarcinoma" concluding that there is a strong and probable causal relation between gastroesophageal reflux and esophageal adenocarcinoma.
Esophageal adenocarcinoma is treatable but rarely curable, mortality is high and successful treatment depends on early detection. Mediscience optical detection of dysplasia, intergrated into an endoscopic examination, can significantly improve the accuracy of biopsy sight selection, thereby increasing the likelihood of early detection of malignancy, and reducing the number of random negative biopsies during an upper gastrointestinal tract endoscopic examination.
Mediscience experience in excitation of important tissue molecules shows improved diagnostic accuracy in the range of 80 to 90% with measurement time a few seconds (real-time). The greatest increase in the incidence of this disease is seen in males, particularly over the age of 60, with the major risk factors of alcohol and tobacco. Since Barrett's esophagus appears to be a predisposing factor for cancer, screening such high risk patients for the development of adenocarcinoma would be appropriate.
Mediscience propriety technology predictably can retro-fit existing and future endoscopes for this and other diagnostic purposes creating intelligent instrumentation for the physician - a significant world-wide market opportunity.
Mediscience has been conducting research in this field since 1988 and presently is conducting two FDA approved studies. "Yale/Mediscience "in-vivo" Phase ll womens health related non-significant risk device was approved January 25, 1999" and FDA approved Phase ll "in-vivo" study for Oral Aerodigestive cancer, approved after successfully completed the Phase I study at Memorial Sloan Kettering New York City. Under the direction of Dr. Stimson Schantz with NCI support. The company intends to additionally file with the FDA in furtherance of Dr. Basuk's work. Both Dr. Basuk's and Dr. Schantz's work concern alcohol and tobacco related cancer.
Mediscience owns exclusive rights to 17 patents in the field of Bio-Optics. Its CD-Scan and other prototype devices are based on its patented optical fluorescence. spectroscopy technology.
With the current medical validation and concern regarding gastroesophageal reflux, there exists a major market opportunity in the United States for Mediscience Technology. In the far east (China, Japan, East and South Africa) the disease is almost epidemic, (130 cases per 100,000 population), indicating mass screening as essential for those and other communities.
Certain matters discussed in this announcement contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 that involve material risks to, and uncertainties in the company's business which may cause actual results to differ materially from those anticipated by the statements made herein.
| Contacts: | Peter Katevatis Pres. | | Dr. Paul M. Basuk |
| 609-428-7952 | | Gastrointestinal Endoscopy |
| | | New York Hospital, Cornell Med Ctr. |
| | | 212-745-4901 |
Top of page
FDA APPROVES PHASE II IN VIVO USE OF MEDISIENCE CD-SCAN OPTICAL SYSTEM AS NON-SIGNIFICANT
RISK DEVICE IN YALE UNIVERSITY/MEDISCIENCE SIGNIFICANT WOMENS HEALTH STUDY.
(March 8, 1999)
CHERRY HILL, NJ, March 8, 1999 - Peter Katevatis announced that Mediscience Technology Corp. (OTC.MDSC),
developer and designer of non-invasive photonic technology used in medical diagnostic instruments
that detect cancer/molecular changes based upon differentiations in the amount of light re-emitted
from malignant and benign tissue, has entered into are search agreement with Yale University under which
Frederick Naftolin Chairman OBGYN Yale University Dept. of Obstetrics and gynecology as the principle
Investigator, will investigate the biological basis of fluorescence as applied to medically significant
OBGYN Health issues using the Mediscience CD-Scan with FDA approval (Jan. 25, 1999) as a
non-significant risk device for the proposed in Vivo Phase II Clinical investigation. In particular, the
autofluorescence from specific areas will be examined to establish non-invasive diagnostic
information of value in specificity and analysis to the OBGYN practitioner. The FDA approved
clinical trial will obtain in Vivo and statistics which will lead o a broader multi-site effort.
Mediscience has been conducting research in this field since 1988 and in a separate
effort successfully completed a FDA approved phase I clinical evaluation with CD-Scan in human
Patients under an NCI supported study of Aerodigesrtive (tobacco related) Cancer at Memorial
Sloan-Kettering Hospital, New York City and is presently positioned to enter FDA Approved
Phase II and Phase II (multi-sites) towards pre-market approval under the continued
direction of principle investigator Stimson Schantz MD.
The potential annual market for clerical cancer and related woman health issues is
approximately $1.25 Billion. Preliminary results of the Yale/Mediscience FDA approved in Vivo
clinical trial are expected during 1999.
Mediscience, a leader in this field, owns exclusive rights to 17 pioneering and early seminal
patents in the field of Optical Biopsy and Optical Mammogrophy. iTS CD-Scan and other prototype
devices are based on its patented optical fluorescence spectroscopy technology.
Certain matters discussed in this announcement contain forward-looking statements within the
meaning of section 27A of the Securities act of 1933 and Section 21E of the Securities Act of 1934
that involve material; risks to, and uncertainties in the company's business which may
cause actual results to differ materially from those anticipated by the statement made herein.
Top of page
MEDISCIENCE US PATENT ISSUED:
Techniques to detect cellular malignancy for PAP SMEAR type samples(June 3, 1997)
CHERRY HILL, NJ, July 1 1997 - Peter Katevatis, President and CEO of Mediscience Technology Corp. (MDSC, OTC
Bulletin Board), announced that MTC has acquired the rights to a new patent for a technique to detect cellular malignancy.
This technique can be used to screen in vitro cell smears.
Using the fundamental principle known as extrinsic fluorescence spectroscopy, it is possible to distinguish normal
cells from malignant cells that have been treated with a fluorescent dye. The fluorescent
dye is preferably absorbed by malignant cells resulting in an enhanced discrimination
fluorescent signature compared to that from normal cells. The technique can he deployed
in an automated system to map the distribution of malignant cells, such as found in
Pap smear-type samples.
The inventors of the patent (#5,635,402: June. 3, 1997) - Robert R. Alfano, Cheng. H.
Liu, Wei L. She, and Yury Budanski -are associated with the Mediphotonics Laboratory and
the Institute for ultrafast Spectroscopy and Lasers at City College of New York. Alfano
and coworkers hold patents for many cancer diagnostic and imaging techniques.
MediScience is a technology development corporation specializing in medical
diagnostic applications that use lasers and optical imaging MTC is receptive to
inquiries on licensing and joint ventures on this and other technologies it owns.
Except for the historical information contained herein, the matters set forth in this
news release arc forward-looking statements that are dependent on certain risks and
uncertainties including such factors, among others, as the Company's ability to
continuously satisfy the FDA's requirements for safety of its devices, its ability
to raise sufficient capital to conduct the human clinical trials necessary to
ultimately prove the safety of its devices and its ability to sell its devices
to health care providers if it is successful in completing their development.
Top of page
MEDISCIENCE ANNOUNCES "INCUBATOR" SPACE ON CAMPUS
Cherry Hill, New Jersey, (March 19, 1997). Mediscience Technology Corp. (OTC-MDSC) announced today that it has executed a lease agreement with City College of New York (CCNY) providing space in an "incubator" for transfer of the technology from Metiphotonocs Laboratory (MPL) at CCNY to MDSC. This lease is the first step in producing units. Prototypes of the Company's diagnostic instruments will be designed and assembled by MPL staff working in concert with personnel from an engineering design firm that has been retained by the company. These units will be used in clinical evaluation. Know-how will be transferred to the company for its manufacturing stages for well defined endoscopic based devices for the gastroenterology, gynecology and urology markets.
The next phase for MDSC will be to create a pilot facility in which several diagnostic instruments will be assembled. The location of the incubator and pilot facility affords Mediscience the advantage of having its design engineers work side-by-side with the MPL research scientists and all within close proximity to the medical institutions in the New York are where the instruments are to be clinically tested.
The Company plans to manufacture and assemble its medical device products on relationship with contract manufactures and/or business partners in the medical device field when the devices are commercialized. Contract manufacturer(s) will be selected from a list of highly qualified companies who are familiar with the regulatory requirements of the FDA for the manufacture of medical devices, who are registered with and in good standing with the FDA.
Except for the historical information contained herein, the matters set forth in this news release are forward-looking statements that are independent in certain risks and uncertainties including such factors, among others, as the Company's ability to continuously satisfy the FDA's requirements for
safety of its devices, its ability to sell its devices to health care providers if it is successful in completing their development.
Mediscience owns exclusive rights to 15 patents in the field of Bio-Medical Optics. Its CD Scan and CD Ratiometer prototype medical devices are based on its patented optical fluorescence spectroscopy technology which can distinguish between normal and cancerous tissue in-vivo (in the body) in a non-invasive manner by optically scanning the surface of suspect tissue with a fiberoptic probe and comparing the resulting fluorescence spectral response to a similar scan of healthy tissue.
Top of page
MEDISCIENCE ANNOUNCES FDA "IDE" APPROVAL(Jan. 8, 1997)
Cherry Hill, New Jersey. January 8, 1997 - Medisciencc Technology Corp. (OTC-MDSC)
announced today that it received FDA approval of its Investigational Device Exemption
to initiate phase II clinical trials with its CD Scan medical device for early stage
detection of cancer. The specific protocol approved for study with this IDE is a
double blind, randomized study of patients with oral leukoplakia. a pre-cancerous
condition in the mouth. Half the patients will be treated with the drug; l3-cis
retinoic acid and the other half with placebo and the entire study population will
he followed up routinely during the study period with the CD Scan and via other
techniques to assess changes of the patient's medical condition. The Company hopes
to demonstrate that its CD Scan device and its Tissue Fluorescence technology can
provide in vivo (in the body) results, non-invasively, comparable to those derviced
from excisional biopsy. If successful in this trial, Mediscience contemplates
expand-ing the study population to gather sufficient data to support premarket
approval. This human clinical study will be conducted at the Sloan Kettering
Cancer Research Center in New York City. The study co-sponsors are Mediscience
and the National Cancer Institute.
"The Company has made tremendous progress in the last year", according to Peter
Katevatis, Chairman of Mediscience. "Approval of this IDE demonstrates that
Mediscience has now developed the know-how and necessary infrastructure to deal
effectively with the FDA on matters of importance both to the Company and the FDA."
Mediscience is already preparing its next IDE submission which is targeted at a
gastrointestinal tract pre-cancerous condition that will employ both the Company's
CD Scan device and its second-generation device, CD Ratiometer. The Company hopes
to be in a position to file for IDE approval to conduct that study later this quarter.
In this planned clinical trial the Company's objective will be to demonstrate the
technical and clinical feasibility of non-invasive detection of pre-cancerous
conditions of the esophagus at an early enough stage where preventive therapy is
highly effective before proceeding into the "pivotal" clin-ical trial to support
premarket approval of its device for that application.
Except for historical Information contained herein, the matters set forth in this
news release are forward-looking statements that are dependent on certain risks
and uncertainties including such factors, among others, as the Company's ability
to continuously satisfy the FDA's requirements for safety of its devices. its
ability to raise sufficient capital to conduct the human clinical trials necessary
to ultimately prove the safety and effectiveness of its devices and its ability
to sell its devices to health care providers if it is successful in completing
their development.
Mediscience owns exclusive rights to IS patents in the field of Bio-Medical Optics.
Its CD Scan and CD Ratiometer medical devices alt based on its patented Tissue
Fluorescence technology which can distinguish between normal and cancerous
tissue in vivo (in the body) in a non-invasive manner by optically scanning the
surface of suspect tissue with a fiberoptic probe and comparing the resulting
fluorescence spectrum to a similar scan of healthy tissue.
Top of page
|